Literature DB >> 14618613

Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells.

Wataru Motomura1, Nobuhiko Takahashi, Miho Nagamine, Mitsuko Sawamukai, Satoshi Tanno, Yutaka Kohgo, Toshikatsu Okumura.   

Abstract

In our study, we examined whether human hepatocellular carcinoma (HCC) expresses peroxisome proliferator-activated receptor gamma (PPARgamma) and the effects of PPAR gamma activation by its selective ligands on cell growth and cell invasion in HCC cells. RT-PCR and Western blot analysis revealed that HCC-derived cell lines, HepG2 and HLF, express PPARgamma mRNA and protein. Luciferase assay in HLF cells showed that troglitazone, a selective ligand for PPAR gamma, transactivated the transcription of a peroxisome proliferator response element-driven promoter in a dose-dependent manner, suggesting that the expressed PPARgamma functions as a transcriptional factor. Not only troglitazone but pioglitazone dose-dependently inhibited cell growth in HepG2 and HLF cells. Invasion assay using a transwell chamber demonstrated that troglitazone also inhibited cell invasion in HCC cells. To examine the mechanism of the troglitazone-induced growth inhibition, we determined p27(Kip1), a cyclin dependent kinase inhibitor, expression by Western blot analysis in troglitazone-treated HLF cells. Troglitazone increased p27(Kip1) in time- and dose-dependent manners, suggesting that p27(Kip1) may be involved in the growth inhibition by troglitazone in HLF cells. To further examine the mechanism of the troglitazone-induced p27(Kip1) protein accumulation, 2 major systems for regulation of p27(Kip1) protein, proteasome activity and Skp2, an F-box protein that targets p27(Kip1) for degradation, were evaluated. Troglitazone potently inhibited proteasome activity and decreased Skp2 protein levels. All these results suggest that human HCC cells express functional PPAR gamma and PPARgamma activation resulted in growth inhibition. The growth inhibition was mediated by p27(Kip1) accumulation, which is induced by both inhibition of ubiquitylation of p27(Kip1) and reduction of degradation activity of p27Kip1 by proteasome. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14618613     DOI: 10.1002/ijc.11561

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Analysis of the role of hepatic PPARγ expression during mouse liver regeneration.

Authors:  Vered Gazit; Jiansheng Huang; Alexander Weymann; David A Rudnick
Journal:  Hepatology       Date:  2012-10       Impact factor: 17.425

Review 2.  Mechanisms by which thiazolidinediones induce anti-cancer effects in cancers in digestive organs.

Authors:  Toshikatsu Okumura
Journal:  J Gastroenterol       Date:  2010-09-08       Impact factor: 7.527

3.  Postponing the Hypoglycemic Response to Partial Hepatectomy Delays Mouse Liver Regeneration.

Authors:  Jiansheng Huang; Andrew E Schriefer; Paul F Cliften; Dennis Dietzen; Sakil Kulkarni; Sucha Sing; Satdarshan P S Monga; David A Rudnick
Journal:  Am J Pathol       Date:  2016-01-06       Impact factor: 4.307

4.  Commentary on prevention a possible drug-drug interaction: is concurrent administration of orlistat and pioglitazone increase the risk of durg-induced hepatotoxicity?

Authors:  Marjan Emzhik; Parvaneh Rahimi-Moghaddam; Soltan Ahmad Ebrahimi; Fariborz Keyhanfar; Ashraf Sadat Moazzam
Journal:  Int J Prev Med       Date:  2015-02-20

5.  Antiproliferative effects and molecular mechanisms of troglitazone in human cervical cancer in vitro.

Authors:  Jinjun Ye; Li Yin; Peng Xie; Jianfeng Wu; Jian Huang; Guoren Zhou; Hanzi Xu; Emei Lu; Xia He
Journal:  Onco Targets Ther       Date:  2015-05-26       Impact factor: 4.147

Review 6.  Cancer biology in diabetes.

Authors:  Shi Sen; Yanzheng He; Daisuke Koya; Keizo Kanasaki
Journal:  J Diabetes Investig       Date:  2014-03-05       Impact factor: 4.232

Review 7.  The Skp2 Pathway: A Critical Target for Cancer Therapy.

Authors:  Zhen Cai; Asad Moten; Danni Peng; Che-Chia Hsu; Bo-Syong Pan; Rajeshkumar Manne; Hong-Yu Li; Hui-Kuan Lin
Journal:  Semin Cancer Biol       Date:  2020-02-01       Impact factor: 17.012

8.  Chondrosarcoma and peroxisome proliferator-activated receptor.

Authors:  K Nishida; T Kunisada; Z N Shen; Y Kadota; K Hashizume; T Ozaki
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

9.  The Role of PPARgamma in Hepatocellular Carcinoma.

Authors:  Ivan Borbath; Yves Horsmans
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

10.  Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis.

Authors:  Davide Genini; Giuseppina M Carbone; Carlo V Catapano
Journal:  PPAR Res       Date:  2008       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.